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Malignant pleural mesothelioma (MPM) is an aggressive serosal tumor, strongly associated with former exposure to asbestos fibers and
for which there is currently no effective treatment available. In human, MPM is characterized by a high local invasiveness, poor prognosis
and therapeutic outcomes. In order to assess molecular changes that specify this phenotype, we performed a global gene expression profiling
of human MPM. Using a 10,000-element microarray, we analyzed mRNA relative gene expression levels by comparing a mesothelioma cell
line to either a pleural cell line or tumor specimens. To analyze these gene expression data, we used various bioinformatics softwares.
Hierarchical clustering methods were used to group genes and samples with similar expression in an unsupervised mode. Genes of known
function were further sorted by enzyme, function and pathway clusters using a supervised software (IncyteGenomics). Taken together, these
data defined a molecular fingerprint of human MPM with more than 700 up- or down-regulated genes related to several traits of the
malignant phenotype, specially associated with MPM invasiveness, protection and resistance to anticancer defenses. This portrait is
meaningful in disease classification and management, and relevant in finding new specific markers of MPM. These molecular markers should
improve the accuracy of mesothelioma diagnosis, prognosis and therapy.
D 2003 Elsevier B.V. All rights reserved.Keywords: Malignant mesothelioma; Pleura; Asbestos; Microarray; Transcriptomics; Molecular marker
1. Introduction The incidence of MM is currently rising worldwide andAsbestos is a leading cause of occupationally related
cancer death. The association between asbestos exposure
and the development of malignant mesothelioma (MM) is
already well known [1]; it develops from the mesothelial
cells lining the serosal cavities and occurs most commonly
in the pleura. Despite a complex etiology, asbestos exposure
is considered as the main cause of MM: about 80% of MM
develops in individuals with higher than background expo-
sure to asbestos [2].0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2003.10.007
Abbreviations: DE, differentially expressed; ECM, extracellular matrix;
HLA, human leukocyte antigen; MM, malignant mesothelioma; MPM,
malignant pleural mesothelioma; fa, sp and co for gene differentially
expressed in respectively mesothelioma ‘‘Fa’’, mesothelioma ‘‘Sp’’ and in
both mesotheliomas
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E-mail address: Bertrand.Rihn@pharma.uhp-nancy.fr (B.H. Rihn).is expected to peak between 2010 and 2020 as a conse-
quence of (i) the widespread use of asbestos since the
second world war, and (ii) the long delay in developing
the malignancy from the initial time of exposure (approxi-
mately 30–40 years). Recent projections suggest about
250,000 deaths by MM over the next 35 years in Western
Europe [3].
For clinician as well as pathologist, MM represents a
big challenge. First, because the differential diagnosis of
the disease from its mimics, largely based on exclusion, is
often difficult. Indeed, a panel of monoclonal antibodies
has been reported, mainly to distinguish MM from
carcinomas, but their diagnosis usefulness remains limited
[4]. Furthermore, by the time the disease is diagnosed, it
is already on advanced stage. Secondly, there is no
standard treatment yet for MM. Mesothelioma is known
as an extremely aggressive cancer that is very difficult to
heal [5]. Once diagnosed, it is uniformly fatal, with a
median survival ranging from 4 to 12 months. Given
these failures, it appears that advance in the management
Table 1
General information about fluorescent signal
MPM ‘‘Fa’’ vs.
MSTO-211Ha
MPM ‘‘Sp’’ vs.
MSTO-211Ha
MET-5A vs.
MSTO-211Hb
Balanced
coefficientc
0.76 0.83 0.97
Elements with
Cy5/Cy3 < 0.5
748 663 176 (156)
Elements with
Cy5/Cy3 > 2.0
363 352 75 (64)
Elements with 0.5\
Cy5/Cy3\ 2.0
6236 6826 6398 (5182)
Elements kept by
‘‘Signal’’ filter
7347 7841 6649 (5402)
Elements kept by
‘‘Expression’’ filter
6939 7568 –
a Mean values of the four independent experiments.
b Based on data from [9]. Between bracket, the number of elements with
a fluorescent ratio in tissues experiments.
c Average fluorescence intensity ratio Cy3/Cy5. Needed to normalize
the hybridization signals for a given pair of probes.
Table 2
Distribution of the 757 genes differentially expressed in mesothelioma
Genes over-expressed in mesothelioma tissues
MPM[MSTO
-211H>MET-5A
MPM>MSTO-
211H=MET-5A
MPM ‘‘Fa’’ 12 (0)a 120
MPM ‘‘Sp’’ 29 (0) 54
Both 21 (1) 50
Genes under-expressed in mesothelioma tissues
MPM\MSTO-
211H<MET-5A
MPM<MSTO-
211H=MET-5A
MPM ‘‘Fa’’ 9 (4)b 244
MPM ‘‘Sp’’ 9 (4) 70
Both 30 (2) 109
a Number between brackets are over-expressed genes characterized by
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pathogenesis and the molecular biology of the disease.
The underlying mechanisms of pleural carcinogenesis
remain to be solved. Altered gene expression was de-
scribed in asbestos fiber-induced carcinogenesis [6,7].
Gene expression profiling, especially using high through-
put microarray methods, has created new possibilities for
the molecular characterization of cancer [8]. In addition,
cancer is now understood as the coordinate action of
clusters of genes. Applied to MM cell lines, microarray
analysis has suggested several genes that may control
MM progression [9,10]. Gordon et al. [11] efficiently
proposed to use microarray gene expression ratio either
to improve distinction between malignant pleural meso-
thelioma (MPM) and lung adenocarcinoma or to predict
treatment outcome in MPM patients [12]. Nonetheless, no
data published so far used microarray technology to
characterize MPM tissue transcriptomes1. Therefore, in
the present study we explored the transcriptome of
MPM tissues using cDNA microarray technology. Our
goal was to examine overall gene expression differences
between MPM and pleural cells with regard to cell line
profiling we obtained previously [9]. The second purpose
was to link these transcriptome disturbances to biological
processes that promote and maintain MPM phenotype by
functional annotation. The third one was to verify Wein-
berg and Hanahan’s [13] assertion that suggested a set of
six effective phenotypic changes in all cancerous cells.
In this report, we performed a 10,000-gene expression
profiling on MPM tissues. Subsequent bioinformatics anal-
ysis identifies three main clusters of altered genes, which
characterized various clinicopathological features of MPM.
We found that MPM particularly enhanced expression of
genes clusters that promote invasion, cell protection and1 See note added in proof.resistance. All three seem sufficient to induce malignant
transformation. These clusters may provide strong candidates
to assist the rational design of new therapeutically strategies.2. Materials and methods
2.1. Cell lines
Mesothelioma cell line MSTO-211H was sourced from
the American Type Culture Collection (ATCC, Manassas,
VA, USA; catalog number CRL-2081). Cells were grown in
T75 flasks with the supplier’s suggested media (RPMI 1640
containing 10% fetal calf serum) at 37 jC with 5% CO2.
Cells were passaged every 2–3 days to maintain growth.
When culture reached confluence, new media was added
and 18 h later, processed for total RNA isolation.
2.2. Tumor tissues
Two tumor specimens, called ‘‘Sp’’ and ‘‘Fa’’, were
obtained at surgery from CHU Coˆte de Nacre (Caen,
France). Samples were snap frozen and kept at  80 jC
until use. Histopathological analysis matched the two tumors
to epithelial subtype of MM (Galateau-Salle, F., personal
communication). Frozen tissues were further homogenized
in a liquid nitrogen grinder (Fisher Bioblock Scientific,
Illkirch, France) and the obtained powder was dissolved in
an appropriate amount of total RNA extraction reagent.
2.3. RNA isolation
Total RNA was isolated using Trizolk Reagent proce-
dure (GibcoBRL, Grand Island, NY, USA). Poly(A)+ RNA
were then selected on Oligotexk matrix (Qiagen S.A.,
Courtaboeuf, France). Both steps were carried out according
to the manufacturer’s recommendations.an expression order MPM>MSTO-211H>MET-5A.
b Number between brackets are under-expressed genes characterized by
an expression order MPM<MSTO-211H<MET-5A.
Fig. 1. Unsupervised clustering ‘‘Experiments Dendrogram’’ obtained from Eisen’s software. The dendrograms show three main clusters of samples identified
by hierarchical clustering of gene expression profiles using two different set of genes, (A) the 5402 validated genes and (B) the 757 DE genes. MPM ‘‘Fa’’, ‘‘Sp’’
and pleural cell (MET-5A) experiments clustered separately as indicated by their corresponding code Fa#, Sp# and Me below the branches of the dendrograms.
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The mRNA profiles were examined with the Human
UnigemVk from IncyteGenomics (Palo Alto, CA, USA)
that allow to screen 10,200 elements including 9984 human
known genes and expressed sequence tags and 216 internal
controls.
Briefly, 1 Ag of mRNA from each sample was reverse-
transcribed in the presence of Cy-conjugated dCTP in order
to generate fluorescent cDNA. Equal amounts of Cy3-
(mesothelioma cells) and Cy5-(tumors) labeled probes were
mixed, denatured and hybridized to the same microarray.
After wash, fluorescent signals were measured for both Cy
channels. These allowed to establish a Cy3/Cy5 ratio,
representing relative expression level. Normalized ratios
were analyzed with bioinformatic softwares.
2.5. Experimental design
As we do not have sufficient non-malignant pleura to
perform tissue/tissue comparison, the mesothelioma cell
line (MSTO-211H) was used as common reference and
compared in four independent experiments to both
MPMs. In addition, we included in the data matrix the
expression profile published previously [9] of pleural cells
(MET-5A, ATCC #CRL-9444) as they were compared in
similar conditions to the MSTO-211H reference. Thus, by
using interarray comparisons, we indirectly selected dif-
ferentially expressed (DE) genes in MPM relative to
MET-5A pleural cells.
2.6. Data filtering
In order to select relevant genes, two selection filters
were applied to the 9984 elements after scanning. First, a
‘‘Signal’’ filter validated signals exceeding background
fluorescence >2.5-fold and covering spot surface >40%.
Only those signals can be used to calculate Cy5/Cy3
ratio. As the reproducibility of results was tested by
quadrupling experiment with the same pair of probes,
we apply a second filter. The ‘‘Expression’’ filter retained
for each tumor genes which displayed a validated fluo-
rescent ratio in at least three on four experiments. Finally,
in order to compare tissue experiments to cell line experi-
ments, we only retained elements that also displayed avalidated Cy5/Cy3 ratio in MET-5A vs. MSTO-211H
profiling. We considered genes DE when their expression
ratio was greater than 2.0, whatever the experiment. After
these filtering, the remaining genes served as starting
point for further bioinformatics and bibliographic analysis.
2.7. Data analysis
To deal with the large set of gene expression data, we
applied two clustering methods to gene expression matrix
in which rows corresponded to genes and columns to
experiments.
Unsupervised clustering does not take advantages of
previous knowledge about analyzed items (genes or
experiments). It only organizes the data into clusters based
on their expression similarity (set of normalized Cy5/Cy3
ratio). In this study, hierarchical clustering was carried out
on both genes and experiments by using the average
linkage method. Eisen’s CLUSTER and TREEVIEW software
(http://www.microarray.org) was used to perform this anal-
ysis and display the results. For each item, the program
provided a single dendrogram in which subsets of items
were joined by short branches if they displayed similar
expression, and by increasingly longer branches as their
similarities decreased.
Furthermore, supervised clustering implies known refer-
ences about items to direct their linkage. Thus DE genes of
known functions were ranked by using GEMTOOLSk soft-
ware v2.4. (IncyteGenomics). The gene hierarchy options
rank genes in clusters according to their involvement in
enzymatic activity (level A), cellular functions (level B) and
pathways (level C). The software allows also to deal with
elements according to one another of their characteristics
(name, Cy3 or Cy5 fluorescence value, etc.). We used this
option to screen gene list for fluorescent signal value over
5000 units. The resulting genes were considered as highly
expressed.
2.8. Gene nomenclature
In this study, genes were named according to human
gene symbols designed by the HUGO Gene Nomenclature
Committee (http://www.gene.ucl.ac.uk/nomenclature/). If
not available, we retained IncyteGenomics gene name.
The following gene name suffix, (fa) for mesothelioma
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mesotheliomas, specified in which MPM each gene was
found DE.3. Results
3.1. Genes DE in mesothelioma
Fluorescent elements kept after processing steps are
shown in Table 1. Most of the elements validated by
‘‘Signal’’ filter display similar expression levels in all
samples as their expression ratio were comprised between
0.5 and 2. After selection by ‘‘Expression’’ filter and
validation in cell line experiment, we obtained a list of
5402 genes on the 9984 initially screened. The entire set
of those genes may be downloaded at http://www.inrs.fr/
INRS-PUB/inrs01.nsf/ inrs01_dossier_view_view/
C3350637CB90F92CC1256CDF00618CF9/$FILE/
visu.html?OpenElement. While the samples were com-
pared to the same reference (MSTO-211H cells), they
could then be compared indirectly each to other. So, the
5402 genes selected by filtering could be ranked in four
expression clusters shown in Table 2. Initial analysis
revealed a total of 757 genes DE in MPM samples (cells
and/or tissues) vs. pleural cells. Interestingly, genes char-
acterized by expression patterns MPM[MSTO-211H>
MET-5A and MPM\MSTO-211H <MET-5A were those
found DE in our previous cell line profiling and con-
firmed in the present MPM tissue experiments. They
corresponded to 62 genes over-expressed and 48 genes
down-regulated in MPM samples as compared to the
pleural cell line. The two other clusters of DE genes,
namely MPM>MSTO-211H =MET-5A and MPM <MSTO-
211H =MET-5A, may emphasize molecular features of
MPM tissues, including tumor heterogeneity.
3.2. Unsupervised clustering
Using the 5402 most valuable transcripts, hierarchical
clustering rearranged gene expression data matrix according
to their degree of similarity. Next, we performed a second
analysis by focusing our hierarchical clustering only on the
757 DE genes extracted from Table 2. Using this gene list asFig. 2. Unsupervised clustering ‘‘Genes Dendrogram’’ obtained from Eisen’s s
hierarchical clustering of the experiments against the 757 DE genes. The differe
indicated by a color code relative to the displayed color index. Gray represents mis
colored bars on the right and expanded in Fig. 3 (all except ‘‘purple bar’’ cluster
Color index:
Column 1 2 3 4 5
Green MET-5Aa Malignant pleural mesothelioma tissue ‘‘Fa’’
Red Malignant pleural mesothelioma cell line MSTO-211H
a Pleural cell line.starting point allowed us to concentrate on the genes that
best represented differences in malignant and normal pleura.
The complete clustering diagrams are only shown for the
second set of genes (Figs. 1 and 2). Eisen’s software applies
clustering algorithm to both experiments and genes. This
approach builds two dendrograms. The ‘‘Experiments den-
drogram’’, as shown in Fig. 1, yielded three clusters that
allowed us to assess the accuracy of the microarray experi-
ments. Interestingly, we can see that the four independent
samples of tumor ‘‘Sp’’ as well as those of tumor ‘‘Fa’’ were
clustered together and discriminated each other. By the way,
both MPMs formed a cluster clearly separated from pleural
cells. The ‘‘Experiments dendrogram’’ revealed similar
linkages between the samples with both set of genes (see
Fig. 1). Nevertheless, the ‘‘Genes dendrogram’’ obtained
from the 757 DE genes analysis showed several clusters of
genes more relevant to characterize MPM phenotypes.
Indeed, this ‘‘Genes dendrogram’’ (Fig. 2, left) and the
associated color map allowed to pull out several distinct
clusters of DE genes as indicated by the colored bars (Fig. 2,
right) and expanded in Fig. 3 to include gene description.
Genes suggested in these zoomed clusters (Fig. 3) are more
expressed in mesothelioma samples than in normal pleural
cells. They function in cell protection and resistance (bleu
bar), invasion (orange bar) and adhesion and recognition
processes (pink bar) as exemplified in the following dis-
cussion. Additionally, the ‘‘purple bar’’ cluster contains
mainly genes consistent with immune responses (not dis-
cussed here).
3.3. Supervised clustering
Table 3 reports the distribution of DE genes in the two
first subsets of GEMTOOLSk hierarchy levels. It also summa-
rizes in secondary subsets, the number of DE genes over-
expressed and under-expressed in mesothelioma samples as
compared to pleural cells. Those numbers were used to
calculate the ‘‘Up/Down’’ ratio with only common DE genes
or all DE genes as exemplified in both last columns (Table
3). Noteworthy, the clusters ‘‘B5000—Adhesion and molec-
ular recognition’’, ‘‘C4000—Environmental response’’ and
‘‘C5000—Ecological interaction’’ contained the most over-
expressed genes in MPM, respectively, 4.4-, 1.8- and 5.2-
fold more over-expressed genes. In cluster C5000, this ratiooftware. Diagram of the gene expression relationships determined using
ntial expression for each transcript (row) in each experiment (column) is
sing data. Gene clusters relevant to MPM phenotype were pointed out by the
).
6 7 8 9
Malignant pleural mesothelioma tissue ‘‘Sp’’
S. Mohr et al. / Biochimica et Biophysica Acta 1688 (2004) 43–6048rose from 5.2 to 8.5 when only DE genes found in both
tumors were included. Such variations marked the contribu-
tion of DE genes that were modulated in the same way in
both MPM tested in this study. Taken together, those relevantFig. 3. Relevant clusters of MPM over-expressed genes analyzed in this work.
adhesion and molecular recognition mechanisms involved in invasion (pink bar),
bar).clusters are particularly interesting to assess pathophysiolog-
ical differences in MPM.
We also used GEMTOOLSk to select, in each experiment,
all elements with a high normalized fluorescent signal (>5000Zoomed clusters from the diagram in Fig. 2. Gene cluster relevant to (A)
(B) invasiveness (orange bar), and (C) cell protection and resistance (blue
Fig. 3 (continued ).
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Table 3
Genes DE sorted by GEMTOOLSk hierarchy clusters
Fisrt Second Second level cluster name Number of genes Number of genes Up/Down Up/Down
level code level code
Up Down
ratio cob ratio totalc
co fa spa co fa sp
A 1000 Oxidoreductases 1 2 1 9 6 3 0.1 0.2
2000 Transferases 3 4 2 10 24 5 0.3 0.2
3000 Hydrolases 3 8 6 4 11 6 0.8 0.8
4000 Lyases 0 0 1 3 1 1 – 0.2
5000 Isomerases 2 0 1 2 2 0 1.0 0.8
6000 Ligases 1 2 2 4 0 1 0.3 1.0
B 1000 Signal transduction and regulation 16 30 16 20 41 13 0.8 0.8
2000 Membrane transport 1 4 1 0 4 5 – 0.7
3000 Protein modification and maintenance 10 2 7 8 13 3 1.3 0.8
4000 Nucleic acid synthesis and modification 4 0 2 3 7 2 1.3 0.5
5000 Adhesion and molecular recognition 13 18 9 5 2 2 2.6 4.4
6000 Electron transfer 0 2 0 1 3 1 – 0.4
7000 Localized and structural proteins 32 47 29 36 86 27 0.9 0.7
C 1000 Metabolism 22 20 23 47 92 27 0.5 0.4
2000 Growth and developement 6 14 5 10 30 7 0.6 0.5
3000 Kinesis 0 1 3 9 18 2 – 0.1
4000 Environmental response 4 6 6 4 3 2 1.0 1.8
5000 Ecological interaction 17 26 4 2 4 3 8.5 5.2
a Genes differentially expressed in both mesotheliomas (co), specifically in mesothelioma ‘‘Fa’’ (fa) or specifically in mesothelioma ‘‘Sp’’ (sp),
respectively.
b Up/Down ratio established as number of genes over-expressed to those under-expressed in both MPM.
c Up/Down ratio established as number of genes over-expressed to those under-expressed in at least one MPM.
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Whatever the sample, those elements could be considered as
pleural markers, useful in pathological application and mo-
lecular characterization of human pleura phenotype, namely
for positive diagnosis and discrimination with poorly differ-
entiated lung carcinomas. Interestingly, some of them, name-
ly ferritin light polypeptide, heterogeneous nuclear
ribonucleoprotein A1, hypothetical protein FLJ23544, lac-
tate dehydrogenase A, ribosomal protein L7a, tumor differ-
entially expressed 1, x006 protein, belong also to DE genes.
Despite their high expression in pleural tissues, ferritin light
polypeptide is up- and the six other genes are down-regulated
when pleural tissue becomes malignant.4. Discussion
As pleural carcinogenesis remains largely unknown,
methods that allow simultaneous analysis of multiple molec-
ular events provide insight into the complex network of
cellular pathways and how they work in the tumor phenotype.
Taken as a whole, the data obtained illustrate a complex
picture of MPM. Perturbation of a significant number of
genes (>700) was observed. To focus our discussion, we
considered that (i) molecular grouping is relevant of behavior
of gene clusters rather than of behavior of single genes, (ii)
relevant clusters of gene expression may be produced by both
clustering methods used in this study, and (iii) as we studied
whole tissues, some down-regulation may not directly reflect
the tumor phenotype but rather a dilution effect on geneexpression. Thus, we selected initially for discussion the
clusters of genes characterized in both clustering analysis
and containing mainly over-expressed elements in MPM.
These clusters of genes fell into three functional classes,
including protection and resistance, invasiveness and im-
mune aspects (not shown). Next, were also included some
relevant down-regulated genes.
4.1. Cell protection and resistance
Clustering results pointed out the mechanisms of cell
protection acquired by MPM (clusters C4000, Table 3, and
‘‘blue bar,’’ Figs. 2 and 3). In vivo, tumor cells develop
under condition of continuous stress and selective pressure
of endogenous systems (host immune defense) or exoge-
nous agents (drug, radiation). This adverse environment
select tumor cell variants, which have induced specific
resistance mechanisms. Deichman [14] characterized two
of these changes in cancer cells, namely an increased
antioxidant activity and the release of immune suppressor
factors. In response to injury, normal cells develop diverse
forms of cytoprotective strategies more generally termed
‘‘stress response’’. The same mechanism seems to be
induced in human diseases as exemplified by studies dem-
onstrating expression of stress proteins in patients with
cancers or other injuries [15]. Adaptation and defense
require the regulation of a specific set of genes. Our primary
study on the cultured MSTO-211H cell line [9] revealed
most of them. The present part of the discussion confirms
the importance of gene expression changes in MPM asso-
Table 4
Elements displaying normalized fluorescent signals >5000 units in all pleural samples
IncyteGenomics gene name HUGO symbol GenBank accession
number
BANP homolog, SMAR1 homolog ? AW958414
calreticulin CALR BG675100
CASP8 and FADD-like apoptosis regulator CFLAR AU117908
choroideremia (Rab escort protein 1) CHM BG291499
DNA fragmentation factor, 45 kD, alpha polypeptide DFFA BF309422
EST, Weakly similar to 2109260A B cell growth factor [Homo sapiens] ? AA827857
ESTs CTMP AI097570
ESTs ? N33584
ESTs ? AI374654
ESTs ? AA772405
ESTs, Weakly similar to 2109260A B cell growth factor [H. sapiens] ? AW820889
ESTs, Weakly similar to A46010 X-linked retinopathy protein [H. sapiens] ? AW341105
ESTs, Weakly similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H. sapiens] ? H48664
eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD) EIF3S2 BG484643
ferritin, light polypeptide (Up, fa) FTL AA554735
glutamate-cysteine ligase, modifier subunit GCLM NM_002061
heterogeneous nuclear ribonucleoprotein A1 (Down, fa) HNRPA1 AU126203
histidine triad nucleotide-binding protein HINT1 BG706444
H. sapiens, clone MGC:12257 IMAGE:3950129, mRNA, complete cds PNLIPRP1 BC005233
hypothetical protein NUP62 BG822825
hypothetical protein FLJ14033 similar to hypoxia inducible factor 3, alpha subunit ? AU119698
hypothetical protein FLJ23544 (Down, co) RPL10 BG679212
KIAA0414 protein ZNF297B NM_014007
lactate dehydrogenase A (Down, co) LDHA AU142698
lymphocyte antigen 75 LY75 BG290654
major histocompatibility complex, class I, B HLA-B BG754309
nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) NFKB2 AL121928
RAB2, member RAS oncogene family RAB2 AW301641
RAB7, member RAS oncogene family-like 1 RAB7L1 BE696116
ribosomal protein L41 RPL41 NM_021104
ribosomal protein L7a (Down, fa) RPL7A AV742224
ribosomal protein S4, X-linked RPS4X BF685834
TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 48kD TAF1A BG505180
TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 250kD TAF1 BE394272
TSPY-like TSPYL AL136629
tumor differentially expressed 1 (Down, co) TDE1 BE740914
v-crk avian sarcoma virus CT10 oncogene homolog CRK BC008506
x006 protein (Down, co) MDS006 BF445491
In bold characters, DE genes with their expression change (up- or down-regulated in mesothelioma samples) and specificity (co, fa, sp) indicated following
gene name between brackets.
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phenotype. Thus, gene functioning in macromolecule sta-
bility and protection were over-expressed in the human
mesothelioma specimens.
4.1.1. Nucleic acid integrity and reparation
MPM in this study over-expressed several genes in-
volved in DNA excision repair and in DNA double-strand
break repair. Most of these genes are linked to the cell cycle
checkpoints. GADD45A is one of the growth-arrest genes.
It is a p53-effector gene known to participate in the global
genomic repair sub-pathway through stimulating nucleotide
excision repair, regulating S and G2/M checkpoints, and
modifying DNA accessibility on damaged chromatin. Genes
of the GADD45 family are transcriptionally activated by
environmental stressors, including UV-radiation, X-rays or
alkylating agents. Thus, the over-expression of GADD45Ain both mesotheliomas may have a protective effect on
cancer cells exposed to DNA-damaging agents. This is
confirmed by the observations that most MPM expressed
a wild-type p53 protein [16]. Mesothelioma ‘‘Sp’’ also up-
regulates cyclin H gene (CCNH), which participates in
excision repair system.
Radiotherapy efficiency is strongly related to the cell
radiosensitivity. Kinetic induction of biochemical pathways
of recognition, signaling and repair of DNA strand breaks
correlates well with clinical radiosensitivity. Two key repair
genes functioning in the same pathway, NBS1 (co) and
ATM (sp), were found more expressed in mesothelioma
samples as compared to pleural cells. Double-strand breaks,
induced by ionizing radiations, activate kinase ATM, which
in turn phosphorylates nibrin (NBS1) and triggers DNA
repair involving the RAD50-MRE11-NBS1 complex [17].
Importantly, genes of those pathways have been considered
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radiosensitivity [18]. Moreover, such DNA damage control
proteins may also affect telomere length. As telomere
erosion limits the cell replicative life span, cancer cells
developed several strategies to avoid telomere erosion and,
indeed, telomerase activity is found in a high proportion of
MM [19]. The precise role of nibrin complex and ATM in
telomere maintenance is unclear, but it has been suggested
that they may act in telomere replication either through
alternative lengthening mechanism or by modifying telo-
meric DNA to facilitate telomerase activity [17,20]. Thus,
the increased expression of several DNA repair genes
supports MPM protection from DNA-damaging agents
and improves their growth ability.
Moreover, DNA topoisomerase activity is required to
control the topologic states of DNA. Gene TOPIIB encod-
ing the isoform II beta enzyme, over-expressed in both
mesotheliomas, is expressed ubiquitously in vivo and found
at a generally higher level in tumors and proliferating cells
[21]. Topoisomerase function is also associated to tumor
resistance and is therefore widely a target of chemotherapies
like doxorubicin and etoposide. In MM, TOPIIB seems
more characteristic of primary tumor tissue and mutations
in TOPIIA can favor cell resistance to etoposide treatment
[22]. Interestingly, Robinson et al. [23] found antibodies to
TOPIIB in 13/14 sera from mesothelioma patients. Such
serological response may be related to the increased expres-
sion of TOPIIB in MPM.
4.1.2. Protein stability and maintenance
Among the various groups of stress proteins, heat shock
proteins (HSP) are synthesized under a variety of stressful
conditions. HSP function mainly as molecular chaperones.
They transiently stabilize, refold intracellular proteins and
prevent intracellular aggregation during stress. In MPM,
the cytoprotection of proteins seems improved according
to an increased expression of a variety of HSP genes
(HSPA1A, HSPA6, CCT2 in both tested mesotheliomas
and HSPA8, HSP105B, CCT6A in mesothelioma ‘‘Sp’’).
Induction of the HSP70 family members, like HSPA1A
and HSPA6, has been considered as an important defense
mechanism in the lung. Their over-expression in lung
tumors was suspected to play an important role in deter-
mining susceptibility to chemotherapeutics agents [15]. A
proteomic analysis of MPM cell response to manumycin
treatment revealed induction of two HSP70 proteins,
which was linked to self-protection of cancer cells to
chemotherapy [24].
In addition, our study revealed over-expression of the
protease-inhibitor genes A2M (co), SLPI (co) and SPINT2
(Sp), which together confer increased protein stability.
4.1.3. Oxidative stress
Many sources of biological processes lead to production
of free radicals like reactive oxygen and nitrogen species.
Moreover, regulation of the cellular redox status is deeplyinvolved in the growth promotion and drug resistance of
cancer cells. Significant modulations in the expression of
several redox-related mRNA were measured by microarray
analysis in this study. Up-regulated genes included SEPP1,
FTL, TXN and SOD2, of which the last three were
characterized in mesothelioma ‘‘Fa’’.
SEPP1 gene encodes an extracellular glycoprotein, the
only selenoprotein known to contain multiple selenocys-
teine residues (up to 10). Most of the known human
selenoproteins play a role in oxidant defense. Selenoprotein
P (SEPP) may also act in oxidant defense as it protects the
extracellular space from peroxynitrite and phospholipid
peroxidation [25].
Protection against oxidative stress is induced by chemo-
protective compounds. Overproduction of ferritin subunits
is one of these possibilities. Ferritin acts as an indirect
antioxidant by sequestering free iron that could otherwise
participate in free radical formation via the Fenton reaction.
In our study, ferritin light polypeptide gene (FTL) is of
particular interest because it is over-expressed in mesothe-
lioma ‘‘Fa’’ and it belongs to genes highly expressed in
pleural samples (see Table 4). Ferritin increase may uptake
iron that was mobilized from asbestos fiber [26] and thereby
protect pleural cells from this source of toxicity. The same
benefit could occur in mesothelioma regarding free iron.
Furthermore, Bomford and Munro [27] reported that an
excess of iron preferentially stimulates transcription of the
ferritin light subunit.
The superoxide radical scavenging enzyme manganese
superoxide dismutase is low in most tumors except in MPM,
as shown by its increased expression in mesothelioma ‘‘Fa’’
(SOD2). Kinnula et al. [28] showed elevated SOD2 mRNA
expression and enzyme activity in several MPM cell lines as
compared to pleural cells MET-5A. Similar results were
obtained by Kahlos et al. [29] when they tested SOD2
immunoreactivity of healthy and malignant pleural tissues.
Most interestingly, both studies confirmed that MPM cells
harboring the highest SOD2 level and activity were the most
resistant to superoxide-generating agents such as menadi-
one. Following another work, Kahlos et al. [30] suggested to
add SOD2 immunoreactivity in the panel of markers
assessed for positive diagnosis of MPM and discrimination
from pleural-located metastatic adenocarcinoma.
Cell redox status is controlled by two keys molecules,
thioredoxin and glutathione. Thioredoxin has cytoprotective
properties against oxidized-protein through its dithiol/disul-
fide exchange activity. Its gene (TXN) was found over-
expressed in mesothelioma ‘‘Fa’’ and MSTO-211H cell line
in our previous study, and at both mRNA and protein levels in
four MPM cell lines by Kahlos et al. [31]. Sun et al. [32]
related TXN up-regulation to the epithelial phenotype ofMM
and probably to their reduced responsiveness to therapy.
There is accumulating evidences that increased TXN expres-
sion in human cancers may result in (i) tumor growth
promotion through inhibition of both spontaneous and
drug-induced apoptosis [33] and in, (ii) reduced sensitivity
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Glutathione participates in detoxification processes via
free radical scavenging, peroxide reduction and conjugation
with electrophilic compounds. Glutathione-associated me-
tabolism seems also important in the pleura. The first and
also rate-limiting step in glutathione biosynthesis is cata-
lyzed by the glutamate-cysteine ligase, which consists of a
heterodimer of a catalytic heavy chain and a regulatory light
chain. The GCLM gene encoding the light subunit is highly
expressed in all samples of pleural origin (see Table 4).
MPM ‘‘Sp’’ over-expressed the GCLC gene of the heavy
subunit. Such an increase was found in five human meso-
thelioma cell lines and interestingly correlated with doxo-
rubicin resistance [35]. Jarvinen et al. [36] confirmed the
increase of both GCL genes at protein level in most cases of
human mesothelioma tissues. Regulation of both GCL
genes could contribute to the drug-resistance phenotype of
MPM.
On the other hand, both MMs and mesothelioma cell line
of this study down-regulated MGST1 gene encoding micro-
somal glutathione S-transferase. Defects in MGST1 gene
have been related to an increased risk of developing MM.
Cohort studies by Hirvonen et al. [37,38] have shown that the
polymorphisms of the two genes MGST1 and NAT2 can
influence incidence of MPM in asbestos-exposed popula-
tions. The risk increased twofold in the MGST1 null geno-
type or the slow acetylation-associated NAT2 genotype and
fourfold in individuals with both alterations. This suscepti-
bility was enhanced in patients exposed to high levels of
asbestos. Accordingly, the second evaluation [38] confirmed
that combination of the two genotypes increases risk of
developing asbestos-related diseases, fourfold for benign
pathology like pleural thickening and eightfold for MM.
4.1.4. Drug metabolism
As shown in the previous cell line profiling [9], genes
directly implicated in the hydrolysis of anticancer drug have
been found to be up-regulated in mesothelioma. We con-
firmed here the over-expression of BLMH (co) and DYPD
(sp) genes in MPM tissues. Bleomycin acts partially through
generation of intracellular reactive species. As noted in
mouse by Gon et al. [39], TXN may exert a protective role
involved in bleomycin resistance. Thus, the increase of TXN
and BLMH was not an artifact of cultured cell lines previ-
ously analyzed [9] and confers an autoprotective equipment
to cells against bleomycin-induced cytotoxicity in MPM.
MPM is a tumor highly resistant to conventional thera-
pies. The mechanisms by which this resistance occurs are
poorly understood. Our study pinpoints the up-regulation of
several detoxification and/or protective genes in MPM
samples. They may function in an integrated manner to
allow tumor cells to deal with adverse changes in their
environment. Furthermore, they provide a powerful starting
point to design new experimental and clinical approaches in
order to reduce MPM resistance.4.2. Tumor invasiveness
In the pleura, mesothelial cells formed a polarized
monolayer anchored to an underlying basement membrane
that lies on collagen and elastic tissue. This organization is
governed by a set of specific structures involving cell–cell
and cell–matrix adhesion molecules. Mesothelial layer is a
dynamic structure, considered as labile as endothelial layer.
An invasive potential may be selected during pleural ma-
lignancy. The invasive behavior of tumor cells depends
upon cellular factors as well as on the molecular character-
istics of the extracellular milieu surrounding these cells.
According to GEMTOOLSk cluster B5000 (Table 3) and
‘‘orange bar’’ and ‘‘pink bar’’ clusters (Fig. 2 and 3),
MPM transcriptomes showed a panel of perturbations in-
dicative of impaired tissue cohesion and simultaneous
remodeling changes.
4.2.1. Adhesion properties
Neighboring mesothelial cells are joined by specific
junctions that involve tight junctions to occlude intercellular
space, gap junctions as mean of communication and des-
mosomes for cell-cell adhesion. Indeed the intramembra-
nous organization of the junctional complexes is under
modification during pleural carcinogenesis. Linnainmaa et
al. [40] observed a defect in gap junctional communication
of MPM cells as compared to benign pleural cells. In our
study several genes encoding cell junction compounds were
down-regulated in MPM samples. TJP2 (co) and RAB13
(co) genes participate in the assembly and activity of tight
junction. TJP2 additionally functions in adherens junction
of polarized cells, as well as the SDCBP gene (co) coding
for syntenin. The later links cell signaling and cytoskeletal
compounds to the extracellular matrix (ECM) syndecans.
MPM ‘‘Fa’’ down-regulates three genes of the catenin
family, namely CTNNA1 (alpha-1 catenin), PKP4 (plako-
philin-4) and VCL (vinculin). Their products belong to the
junction-associated proteins. They form the cytoplasmic
face of the adhesion plaques involved in contact with the
cytoskeletal filaments. Together, these findings indicate a
disturbance in cell–cell adhesion systems that may facilitate
anarchic growth.
Nevertheless, tumor invasion requires the formation of
intercellular adhesions. During embryonic development or
adult wound healing, cells are joined by transient adher-
ences without organized structure. These particular types
of adhesion receptors are essential in tissue development
involving cell migration. In cancer, the same mechanisms
may contribute to the dissemination of tumor cells in the
surrounding stroma. Hence, cell adherence protein-encod-
ing genes will be of great interest. Several genes
encoding cadherin, cell adhesion molecule and integrin
seem to function together as assessed by their differential
expression.
Cadherins are key molecules in mutual cell interaction in
primary embryonic tissues. Changes in the cadherin reper-
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in tumor progression context. The osteoblast-cadherin gene
(CDH11) was found over-expressed in both MPM. CDH11
products mediate cell adhesion by interacting with them-
selves in a homophilic manner. In rat, CDH11 is described
as the first transcript strongly expressed in the dispersed and
invading mesenchymal cells. Moreover, it is considered as a
molecular marker of the mesenchymal phenotype [41] and
thus was found in mesothelial cells by Shibata et al. [42].
Specific induction of mesenchymal-type cadherins in MPM
contributes to the invasive behavior of malignant cells
through mediating cancer-stromal interactions. In breast
cancer, Pishvaian et al. [43] found CDH11 mRNA and
protein in the most invasive cell line variants. They local-
ized the protein in membrane at cell contact sites and/or
cytoplasmic projections. In other carcinomas, CDH11 over-
expression is shown during the cadherin pro-adhesive/pro-
migratory switch. The latest ‘‘mesenchymal’’ form corre-
lates with more aggressive and invasive subset of tumor
[44]. The up-regulation of the CDH11 in MPM marked the
mesenchymal origin of MPM despite its epithelial histotype,
and its invasive phenotype. MPM ‘‘Sp’’ up-regulates
CDH19 and down-regulates PCDH7, both of the less
annotated members of the cadherin family.
Besides cadherins, immunoglobulin-like cell adhesion
molecules (CAMs) play a critical role in malignancy.
Among the most intriguing CAMs involved in tumor
progression is the neuronal family (N-CAM). MPM
‘‘Sp’’ over-expressed two of them, NEO1 and CNTN1.
Both were found on growing nerve cells in the develop-
ing nervous system but NEO1 was also described in
mesoderm-derived embryonic tissues. Contactin-1 (gene
CNTN1) is a fibronectin receptor and neogenin-1 (gene
NEO1) a netrin receptor, two guidance molecules that
initiate signaling pathways controlling axonal growth and
migration programs. Their over-expression in cancer may
lead to formation of directed protrusions that allow
growing cells to migrate in their surrounding environ-
ment. Each MPM increased cytokine-inducible CAM,
namely ICAM1 (fa) and VCAM1 (sp), that have been
implicated in tumor progression. Both were already
detected on MM cells by immunohistologic examination
of tissue sections [45]. VCAM1 marked preferentially
epithelial-like cell of MM and seemed cytokine-depen-
dent, whereas ICAM1 did not need such a stimulation to
be expressed [45]. They bound ligands of the integrin
family highly expressed on leukocytes and endothelial
cells. In pleural diseases involving inflammation and
immune reaction, CAMs mediate interactions that facili-
tate stromal remodeling and tissue infiltration. These
effects might in turn promote tumor growth and dissem-
ination by endothelial cell adhesion, angiogenesis and
recognition of tumor cells by the immune system.
Integrins anchored cell to their surrounding ECM
through focal contact and cells by cell adherence. Numer-
ous evidences have implicated integrin network in patho-logical conditions, such as tissues healing and solid tumor
progression. Their functions are essential in invasion by
mediating cell binding on ECM proteins and by transduc-
ing ECM-dependent signaling events that control cell
migration, as well as growth and gene expression of
matrix degrading enzymes [46]. MPM ‘‘Fa’’ over-
expressed a large panel of integrin genes, including
ITGAX, ITGAM, ITGA1 and ITGA4. MPM ‘‘Sp’’ over-
expressed the only ITGBL1 gene. Such heterogeneity in
the alpha-integrin pattern of expression was previously
shown by Barth et al. [47] in MPM. Reports on integrins
expression in the pleura agree that (i) mesothelial cells
only expressed one alpha chain of integrin, the alpha-V,
(ii) integrins beta-1 is expressed in all subtypes of MPM,
and (iii) mesothelioma cells expressed alpha-3, -5 and -6
chains. Despite alpha-3 chain was not screened in the
current microarray, our previous macroarray study [9]
demonstrated ITGA3 increase in MSTO-211H vs. MET-
5A. As h1 subunit was present in all MPM, the over-
expression of several ITGA genes could result in an
excess of mixed a/h1-chains receptors on MPM cell
surface. They offer a vast array of possibilities for MPM
cells to migrate to soluble and substrate bound fibronectin
(a3 and a4), laminin (a1 and a3) and collagen (a1 and
a3) or to link VCAM1 (a4). On the other hand, both
MPM down-regulated ITGA2 gene, which allows cell
migration. With h1 chain, it forms the VLA-2 receptor
for laminin, collagen, fibronectin and E-cadherin. In addi-
tion to its role in cell migration, ITGA2 might be an
important element in the structure of the ECM. Its binding
activity also controls force generation and organization of
newly synthesized matrix. ITGA2 protein has not been
detected in MPM specimens studied by Barth et al. [47]
and in many carcinomas it is often down-regulated [46].
The ITGA2 loss could also be related with the global
fragility of ECM in MPM as suggested by data shown
below and the frequent loss of the pro-adhesive E-cadherin
in many neoplasm. During progression marked changes in
the integrins dynamics occurred, which may facilitate
interaction with the ECM proteins and promote invasion.
Pleural carcinogenesis study in rat suggested that ITG-
dependent signaling may be targeted by asbestos fibers
[6].
Among heparan sulfate-containing proteoglycans, a frac-
tion was recovered as cell-associated compounds. This form
of proteoglycans was mainly represented by syndecan-1, -2
and -3 in MM cell lines [48]. Syndecan-2 gene (SDC2) was
over-expressed in both MPM. With integrins, they served as
receptor of the surrounding matrix that may be involved in
motility and invasiveness of MM cells in vivo. SDC2 is
highly expressed in tissues of mesenchymal origin and its
increase correlates with the epithelial differentiation of
MPM cells [49]. Thus, SDC2 over-expression confirmed
both their mesenchymal origin and their epithelial pheno-
type. More generally, syndecans act as cell-surface co-
receptors for a variety of extracellular ligands, thereby
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cellular processes including, cell adhesion, migration and
proliferation (for review see Ref. [50]). For example, growth
factors like those of the FGF family are known to bind
syndecans. As each MPM over-expressed at least one FGF
gene (FGF7 (fa) and FGF9 (sp)), syndecan could emphasize
FGF activity by increasing their effective concentration to
the appropriate cell surface, thereby enhancing their ability
to induce downstream signaling.
4.2.2. ECM composition
Besides the tumor cells themselves, stromal components
are likely to modulate the malignant phenotype. The ECM is
a key element of the local microenvironment. Its qualitative
and quantitative composition is under continuous modifica-
tions in the living tissues. This dynamic process can
influence cell behavior in both malignant and non-malignant
tissues. Cellular interactions within ECM initiate signaling
pathways and gene expression programs driving adhesion,
spreading and survival. Thus, ECM remodeling participates
actively in the molecular cross-talk at the invasion front.
Mesothelial cells have the ability to produce and release
ECM components in vitro and in vivo. Also, they contribute
to the dynamics of their surrounding microenvironment
[51]. MM cells conserved this feature by producing glyco-
saminoglycans and several structural and adhesive proteins
of the ECM. Previous data demonstrated that production
and release of ECM macromolecules reflect the differenti-
ation state and/or the origin of MM [52].
Human MM cells in vivo are often embedded in a
diffuse collagenous matrix. Several genes of the collagen
family were enhanced in the studied MPM (see ‘‘orange
bar’’ cluster, Fig. 3). Commonly over-expressed genes
included those of fibrillar forming collagens COL1A1
and COL11A1. In embryo and young animal, type I
collagen consists mainly of three coiled subunits composed
only of alpha-1 chain, whereas in adult it contains also one
alpha-2 chain. This embryonic-type collagen is very sen-
sitive to protease degradation. Furthermore, it is relatively
poor in intermolecular cross-links that stabilize the stag-
gered array of collagens in the fibrille structure. This
bound involves specific oxidized lysine and hydroxylysine.
We concomitantly found a down-regulation of PLOD2
gene (co), which encoded a protein catalyzing lysine
residues hydroxylation. In addition, Ehlers et al. [53]
recently showed that the invasive potential of MSTO-
211H mesothelioma cells was promoted on collagen I
culture as compared to MatrigelR (basement membrane
mimic) culture. COL11A1 is known to regulate fibrillo-
genesis and cohesion in the cartilage, but accumulated also
in other non-cartilaginous tissues where its expression was
restricted mostly to cells of mesenchymal origin [54].
MPM ‘‘Sp’’ was highly enriched in collagen transcripts
of alpha-1 chain types IV, X (cartilage collagen) and XVI
(fibril-associated collagen). They localized respectively in
basal lamina, growing area of cartilage and in the amnion.Interestingly, Bensadoun et al. [55] noted that following
lung injuries, early collagen synthesis may occur within
versican-rich areas of the ECM, and the deposition of
versican is specific to early remodeling sites in lung dis-
eases. Versican is a large chondroitin sulfate proteoglycan of
the ECM encoded by CSPG2 gene. Malignant transformed
cells are often associated with an elevated production of
proteoglycan such as versican. Actually in MM, chondroitin
sulfate proteoglycans are mainly organized as versican in
the extracellular medium. According to Dobra et al. [49], an
excess of matrix proteoglycan (versican and biglycan) is
more indicative of the fibroblast-like phenotype of MM
cells. In contrast, the enhanced expression of the CSPG2
gene in both epithelial mesotheliomas we have analyzed
demonstrated also its involvement in the epithelial histo-
type. Versican was reported as an anti-adhesive molecule
involved in the regulation of substratum adhesion. Increased
neoplastic synthesis and deposition of versican may facili-
tate remodeling of the ECM and therefore invasion.
4.2.3. Metastatic potential
MM spreads rapidly along the serosal surface. Despite
this high local invasion, distant metastases are unusual
compared to other tumor entities. This behavior could be
related to differential expression of several genes, which
may restrict tumor dissemination to a localized zone.
In order to migrate and infiltrate into areas of noncan-
cerous surrounding tissues, tumor cells have to cross several
barriers. Complex molecular ‘‘cross-talk’’ between host and
tumor cells leads to increase proteolytic enzyme activity at
the invasion front and facilitates thus tumor dissemination.
The main classes of proteases, which have been implicated
in the process of tumor invasion and metastasis, include
metalloproteinases, serine proteases and cathepsins. Few
data on DE genes were directly related to proteases them-
selves. However, much data concerned regulators of those
degrading systems. It should be pointed out that tissues vary
considerably in their ability to withstand tumor invasion.
Such resistance may be due to greater mechanical strength
of tissues or to anti-proteolytic factor release that inhibits
proteases. The data obtained in both MPM support the
second mechanism of action. Indeed, invasion can be
confined locally in MPM by up-regulating several inhibitors
of protease. TIMP3 gene (co) encodes a natural inhibitor of
various matrix metalloproteinases (1, 2, 3, 7, 9, 13, 14 and
15). Uria et al. [56] detected TIMP3 mRNA in breast
carcinomas and several normal tissues with hypothetic role
in the control of tissue turnover and remodeling. RT-PCR
analysis of eight MM cell lines by Liu et al. [57] revealed a
broad spectrum of matrix metalloproteinases and related
TIMP inhibitors expression. All cell lines expressed matrix
metalloproteinases 1, 2, 3, 9 and TIMP1, -2, -3 at mRNA
level. Production of several matrix metalloproteinase pro-
teins was confirmed by Western blot and gelatin zymog-
raphy. Furthermore, the A2M gene was over-expressed in
both MPM. Alpha-2-macroglobulin is active against a broad
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the receptor-bound form as shown by Kobayashi et al. [58].
In a striking demonstration of A2M activity in patients,
secondary development of the prostate cancer in the bone
was significantly correlated with a serological drop in A2M
concentration [59]. MPM ‘‘Sp’’ over-expressed a third anti-
protease gene, namely SPINT2 (also called KOP). It func-
tion mainly associated with heavy chains in inter-alphatryp-
sin inhibitor complex. Heavy chains ensure anchorage to
matrix hyaluronan and regulate the protease activity of the
SPINT2 catalytic subunit. SPINT2 has a serine protease
inhibitor activity against plasmin, leukocyte elastase, trypsin
and two proteases of the coagulation pathway, factor Xa and
kallikrein. One of these targets, namely factor Xa, was also
found over-expressed in MPM ‘‘Sp’’. Numerous observa-
tions suggest the protective role of SPINT2 in carcinogen-
esis. Yoshida et al. [60] localized SPINT2 in the surrounding
connective tissue of cancer invasion where it is supposed to
play an active role in protecting the remodeling site. In
ovarian cancer, transient expression of SPINT2 reduced cell
invasion without affecting cell proliferation, adhesion and
migration potentials, as compared to those from parental
cells. The same SPINT2-transfected cancer cells in animal
model lost their ability to disseminate peritonealy [61]. The
anti-metastatic effect is naturally dependent on the SPINT2
activity as it prevents the serine protease-dependent matrix
degradation. It may also involve interference with the MEK/
ERK pathways, with subsequent suppression of cell motility
[61]. SPINT2 complex is increased in prostatic cancer, but
as compared to A2M activity, it also efficiently inactivates
the receptor-bound plasmin [62]. It is noteworthy that the
three anti-protease genes described above were found in
invasion-related clusters pooled by unsupervised analysis,
namely ‘‘pink bar’’ for A2M and ‘‘orange bar’’ for SPINT2
and TIMP3 (Fig. 3A and B). As a result, protease inhibitor
over-expression in MPM could act (i) in defense and repair
events associated with tissues destruction and remodeling,
and/or (ii) in protection of tumor cells surface proteins,
which are likely to contribute to the local cell invasion
processes encountered in MPM.
Among ECM components, two classes of molecules
were of particular interest in defining restricted invasion
of MPM. Each of the studied MPM showed increased
expression of a tenascin gene, HXP for ‘‘Sp’’ and TNXB
for ‘‘Fa’’. Tenascin are large multimeric ECM glycopro-
teins. They are believed to be involved in inhibition of
cell migration, in supporting growth of epithelial-type
tumor, and in inflammation and fibrosis. Mesothelial cells
are able to produce tenascin. Their expression is in-
creased, probably through cytokines stimulation, during
pleural inflammation and fibrosis of various etiologies
including asbestos [63]. HXB was firstly discovered
because of its over-expression in many tumors [64].
HXB hexamer was found in ECM of mesenchymal
tissues and associated with active epithelial-stroma inter-
actions. Moreover, it was selectively expressed at sites oftissues remodeling in the developing and pathological
connective tissues. TNXB was recently identified as a
member of the tenascin family. Tumor cells inoculated in
TNX knock-out mouse showed improvement in cell
invasion behavior and metastasis formation [65]. Induc-
tion and activation of matrix metalloproteases were sug-
gested as molecular basis of this promotion and as result
of TNX silencing. TNX over-expression may prevent
invasion and metastasis formation. An additional regulat-
ing role for TNX in vasculogenesis and angiogenesis was
reported by Ikuta et al. [66].
The second set of relevant genes, including THBS1 (co)
and THBS2 (sp), encodes thrombospondin 1 and 2, respec-
tively. Both are transient matrix glycoproteins secreted by
many cell types in developing and repair tissues. They may
interfere with tumor growth, angiogenesis and metastasis
but controversy exists about their biological functions. As
assessed by RT-PCR, THBS1 was highly expressed in 74/78
MPM tumors compared with either normal pleura or the
surrounding normal lung [67]. In addition, a significant
THBS1 decrease in the rare cases of MPM-derived lymph
node metastases was found in this study. More generally,
THBS1 over-expressing melanoma, breast and lung tumors
showed reduced metastatic capabilities. Breast tumor-de-
rived cell lines from the same patient, with equal tumor
potential, exhibited lower frequency of metastases if they
produced and secreted THBS1 [68]. Remarkably, THBS1
modulates cell responses through cell adhesion receptors
integrin alphaV-beta3 or CD36, the latter was also up-
regulated in both mesotheliomas. No report has assessed
THBS2 involvement in MPM. However, as it shared com-
mon structural motifs with THBS1, one could suppose that
both thrombospondins overlap in their regulatory functions
as serine proteinase inhibitor or angioinhibitor [69]. THSB2
over-expression in stromal tissue may be related to a host
anti-tumor defense mechanism as it was supported in a skin
carcinogenesis mouse model [70].
A final panel of genes coinciding with metastatic
transmigration was found down-regulated in our MPM.
Most of them are metastatic markers. NME1 gene (co),
also named NM23H1, belongs to the nm23 nucleoside
diphosphate kinase family. In vivo, NM23 enzymes have
been originally identified as suppressor of metastasis [71].
Nevertheless, clinical studies showed contradictory results,
alternatively associated with reduced or increased meta-
static potential. In fact, nm23 kinases’ role is type-depen-
dent and tissue-specific. For example, the NM23H1
exhibits different, if not opposite, biological properties in
carcinomas of two different origins (breast and ovarian)
[72]. In lung tumors, Gazzeri et al. [73] found better
correlation with tumor progression rather than influence
on metastatic potential. It was recently shown in NSCL
cancer [74] that NME1 expression level selectively inhibits
the formation of systemic metastases without influencing
local malignant cell spreading at pleural or lymphatic sites.
Altogether, these observations preferentially suggest an
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ness of MPM. Previous macroarray results on cell lines
revealed also over-expression of the NM23-H4 gene [9]. It
would be interesting to study the involvement of NM23
balance in MPM at the enzymatic level.
On the cell surface protein tyrosine kinases EPHA2 (gene
EPHA2, (co)) form a receptor for either ephrin molecules or
B61 endothelial protein. This class of enzymes is frequently
over-expressed in metastatic cells as it was highly detected
in both metastatic melanoma tissues and high metastatic
melanoma cell line variants [75]. Western blot and immu-
nohistochemical analysis of prostate cancer samples showed
10–100-fold more EPHA2 protein in metastatic vs. non-
invasive cells [76]. Their activation in tumors may control
key events in tumor vascularisation and progression through
cell–cell/matrix contacts and cell migration as it was shown
in neuronal development. Furthermore, EPHA2 induced
apoptosis by impeding anti-apoptotic pathway through focal
adhesions [77]. AXL gene (sp) encodes another receptor of
tyrosine kinase family found over-expressed in Western blot
screening of these receptors in human colon carcinomas
[78]. AXL displayed up to a 10-fold increase in metastatic
structure as compared to malignant or normal tissues.
Two hyaluronan receptors genes are also down-regulat-
ed, namely CD44 (co) and HMMR (fa). Cell immobilization
is often concomitant with reduction in the hyaluronan ECM,
with failure of their cell surface receptors and with increased
level of hyaluronidase. Reduction of both ubiquitous recep-
tors for hyaluronan may thus benefit the local invasion of
MPM rather than distant propagation. CD44 decrease was
unexpected, since it is considered as positive MPM marker
with highest expression in epithelial subtype [79]. Hyalur-
onan receptors may be important for MM cell migration and
metastasis formation in their hyaluronan-enriched matrix.
Nevertheless, CD44 expression is subject to complex reg-
ulation, including differential use of 10 alternative exons
that generates multiple splice variants. Moreover, Asplund
and Heldin [80] evidenced no strict correlation between the
hyaluronan binding activity of MM cells and their levels of
surface CD44 molecules. Activation of the other hyaluronan
receptor, HMMR, promotes focal adhesions through protein
kinase SRC signal transduction. The loss of HMMR
impedes this response and, as a result, tumor cells became
unable to promote cell mobility and to form metastases [81].
HMMR mRNA was found over-expressed in pancreatic
tumor cell lines with high invasive potential and protein
staining was increased in breast cancer lymph node metas-
tasis [82]. Hyaluronan binding to either CD44 or HMMR
has common benefic role in promoting metastasis in gastric
cancer and glioma. Thus, lack of hyaluronan receptors could
be well correlated with an impaired ability to form metas-
tasis in MPM.
The 5T4 antigen (gene TPBG, (co)) was originally
identified by a monoclonal antibody raised against a
human placental trophoblast glycoprotein. It has a restrict-
ed and low pattern of expression in normal adult tissuesbut is selectively detected in a wide range of carcinomas
[83]. A more detailed assessment of 5T4 expression in
carcinomas has indicated a striking correlation between the
5T4 immunoreactivity in tumor cells and their metastatic
spread [84]. Microscopic observations of 5T4-expressing
tumor cells by Carsberg et al. [85] showed that 5T4 was
localized in the plasma membrane at cytoplasmic projec-
tions and that positive cells exhibited an elongated fusi-
form morphology. These evidences argue in favor to direct
function in placentation and metastatic processes by mod-
ulating cell adhesion and motility. The decrease of 5T4 in
both MPM may also contribute to the maintenance of
localized invasion.
These observations lead to the hypothesis that combined
changes in cell contacts and tissue architecture would gen-
erate permissive conditions for MPM cell spreading without
excluding restricted dissemination. Both conditions are like-
ly to co-exist in the tumor microenvironment. This detailed
picture will help to target new molecules to critical point in
specific invasion patterns (as shown in MPM), promoting the
emergence of so-called ‘‘stromal therapy’’ [86].
Substantial efforts have been made to elucidate MM
biology. In this study, we report the identification of several
hundred of DE genes in MPM, both shared or unique to
each MPM tissue. Several important conclusions can be
drawn from these findings. Microarray analysis of MPM
transcriptome has been successful in discriminating malig-
nant from normal pleural samples and in grouping the four
independent experiments of each MPM samples according
to their origin. Specific changes in several clusters of gene
expression give promise for a better understanding of the
mechanisms underlying MPM phenotype. Indeed, function-
al characterization of the most relevant clusters of gene
expression advanced our knowledge of MPM clinicopatho-
logic features, especially in regard to increased local inva-
sion properties and to tumor protection and resistance to
anti-cancer defenses. Success of such approach is indicated
by the fact that several of the DE genes found in our study
have been previously associated either with MM or with
tumor phenotype in numerous studies conducted on single
gene.
Further characterization of those DE genes will be
helpful in defining a panel of diagnostic or prognostic tumor
biomarkers, and molecular targets for therapeutics or pre-
venting agents. It opens new opportunities for the develop-
ment of anti-tumor therapies. MPM is a particularly
interesting model in designing in situ delivered therapies
because of its restricted dissemination and because of its
high resistance against therapies. Moreover, its close corre-
lation with asbestos exposure makes the identification of
‘‘at-risk’’ population reasonably more easy, a prerequisite
for future application of preventing strategies.
Validation and functional analysis of these expression
data on a larger panel of MPM are yet to be described.
Further studies are also necessary (i) to compare gene
expression profiles of epithelial mesotheliomas to other
S. Mohr et al. / Biochimica et Biophysica Acta 1688 (2004) 43–6058MM histotypes as well as pulmonary tumors, and (ii) to
analyze more accurately mesothelioma cells in situ using
combination of microdissection and microarray technolo-
gies (Mohr et al., [87]).
Note added in proof
At the time we wrote the paper, the study of Singhal et
al., (Clin. Cancer Res., 9 (2003) 3080–3097) on mesothe-
lioma tissue specimens was not yet published.Acknowledgements
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